Mesothelioma "applied research foundation" (Ombudsman) to finance research projects since 2000. The Ombudsman awards after it recently funded seven projects for $ 700,000, amounted to $ 1.7 million worldwide.
Seven candidates were chosen after a managed peer review Advisory Board of science "the Ombudsman and the Council Presidency and the President, Dr. Raafat Hassan. Hassan is the current "senior investigator" in National Cancer Institute. The selection process "institution chosen proposals will lead to new treatment options for patients with mesothelioma. It is clear that the "mediator" Foundation grant program continues to have a significant impact on research mesothelioma globally ".
With estimated 90 people-a with mesothelioma annually, world therapy research and new treatments are always welcome. The Ombudsman's mission is to end the suffering caused mesothelioma through development of new treatments and healing.
Mesothelioma Cancer rare almost unit causes asbestos fibers. Featuring a long latency period and short-age patient after diagnosis. These factors make it difficult to diagnose and treat mesothelioma. Mesothelioma treatments available include treatment with surgery, chemotherapy and radiation, but there is no cure.
Dr. Lee Krug, new Science Advisory Board Chair of medium to enterprise administrator mesothelioma at Sloan Kettering Cancer Center, we identified seven special grants for funding, but certainly I wish we could fund more. "
Seven intermediate Foundation-funded project:
Chung Dr.Huang, Stanford University: "development of biomarker mesothelioma" marched "network analysis" flexible organizational unitfengzhi Dr.mikrorna me, Roswell Park Cancer Institute: validation of protein-dye antiabobetotik novel for mesothelioma treatmentDr. Ben Liu-"Lance s. ruble & Ferraro law firm grants", University of California in San Francisco: Absorb liquids provide targeted skaff RNA therapies for all subtypes of mesotheliomageneration Dr. Orr-"Franz Memorial Scholarship" lushforest "alert" University College of Medicine: germ line DNA sharing and Web topics with mesotheliomaDr. R. Manish Patel, University of Minnesota: Assessment of predictive host immune response biomarkirs of measles virus intrablioral management of aunkolitik in clinical trial phase I specifically for patients suffering from MesotheliomaMorgan Dr. Schulz, Brigham and women's Hospital: localized tumor "nanobartikli polymeric drug delivery" of treatment of malignant mesothelioma "Shilo Dr. Varghese, University of Maryland School of medicine": "Briklinikal development" novel therapy for malignant peritoneal entry "misothiliomathis" released on Tuesday 15 February 2011 at 6: 53 pm and is filed under General, news. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.
No comments:
Post a Comment